Capital Fund Management S.A. bought a new stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 29,497 shares of the company’s stock, valued at approximately $1,040,000.
Several other large investors have also modified their holdings of MRVI. GSA Capital Partners LLP acquired a new position in Maravai LifeSciences in the first quarter valued at about $357,000. C M Bidwell & Associates Ltd. purchased a new position in shares of Maravai LifeSciences during the 1st quarter worth approximately $38,000. Vaughan Nelson Investment Management L.P. acquired a new stake in Maravai LifeSciences in the 1st quarter valued at approximately $21,785,000. Massachusetts Financial Services Co. MA raised its position in Maravai LifeSciences by 12.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 8,965,103 shares of the company’s stock valued at $316,198,000 after purchasing an additional 962,082 shares during the period. Finally, Teacher Retirement System of Texas lifted its stake in Maravai LifeSciences by 6.7% during the first quarter. Teacher Retirement System of Texas now owns 22,950 shares of the company’s stock worth $809,000 after purchasing an additional 1,433 shares in the last quarter. Institutional investors and hedge funds own 51.02% of the company’s stock.
Maravai LifeSciences Trading Down 0.3 %
NASDAQ MRVI opened at $20.87 on Friday. Maravai LifeSciences Holdings, Inc. has a 52 week low of $20.11 and a 52 week high of $61.02. The firm has a 50 day moving average of $26.22 and a two-hundred day moving average of $31.16. The company has a quick ratio of 6.21, a current ratio of 6.75 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $5.33 billion, a PE ratio of 12.42 and a beta of 0.53.
Wall Street Analyst Weigh In
Several research firms recently issued reports on MRVI. Morgan Stanley cut their price objective on Maravai LifeSciences from $49.00 to $35.00 and set an “overweight” rating on the stock in a report on Monday, August 8th. Credit Suisse Group initiated coverage on shares of Maravai LifeSciences in a research report on Wednesday, August 24th. They set an “outperform” rating and a $34.00 price target on the stock. Robert W. Baird cut their target price on shares of Maravai LifeSciences from $40.00 to $34.00 in a research note on Friday, August 5th. TheStreet cut shares of Maravai LifeSciences from a “c-” rating to a “d+” rating in a research report on Tuesday, July 26th. Finally, The Goldman Sachs Group cut their price objective on Maravai LifeSciences from $44.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, July 14th.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.